Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Cash from Financing Activities (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Cash from Financing Activities data on record, last reported at $1.3 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 249.48% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $2.4 million, down 99.46%, while the annual FY2025 figure was $2.4 million, 99.46% down from the prior year.
  • Cash from Financing Activities reached $1.3 million in Q4 2025 per CLDX's latest filing, up from $774000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $436.1 million in Q1 2024 and bottomed at -$25000.0 in Q2 2021.
  • Average Cash from Financing Activities over 5 years is $46.9 million, with a median of $560000.0 recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: plummeted 100.02% in 2021, then surged 62740.35% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $426000.0 in 2021, then soared by 227.46% to $1.4 million in 2022, then surged by 15482.37% to $217.4 million in 2023, then tumbled by 99.82% to $386000.0 in 2024, then soared by 249.48% to $1.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $1.3 million in Q4 2025, $774000.0 in Q3 2025, and $63000.0 in Q2 2025.